1. ALLA AKTIER
  2. NYHETER
  3. ASARINA PHARMA

Asarina Pharma

Nyheter Asarina Pharma Nyheter alla bolag

Bulletin from the extraordinary general meeting and first control meeting in Asarina Pharma

MARKN.

Asarina Pharma AB (publ) held on 21 August 2024 an extraordinary general meeting, and first control meeting, at which the shareholders resolved that the company would enter into voluntary liquidation. The general meeting adopted the following main resolutions.

Resolution on voluntary liquidation
The general meeting resolved in accordance with the board of directors' proposal that the company shall enter into voluntary liquidation in accordance with Chapter 25, Section 3 of the Swedish Companies Act. The resolution on liquidation is proposed to take effect as of 1 December 2024. The reason for this is that payments are expected to be received by the company's Danish subsidiary Asarina Pharma ApS during November. The distribution of any liquidation proceeds is expected to take place in connection with the expiry of the time for calling unknown creditors, or at the latest in connection with the presentation of the liquidator’s final report. No probate proceeds are prudently anticipated. The board of directors had not presented a proposal for a liquidator to the general meeting.

For further information, please contact:
Paul De Potocki, Chairman of the Board of Directors
Phone: +46 (70) 669 9618
E-mail: paul.depotocki@telia.com

Jakob Dynnes Hansen, CFO
Phone: +45 5132 3698
E-mail: jakob.dynnes@asarinapharma.com

About Asarina Pharma
Asarina Pharma is a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive Compulsive Disorder that still lack safe, efficacious pharmaceutical treatments.

The Company's Certified Adviser is Carnegie Investment Bank AB (publ). E-mail: certifiedadviser@carnegie.se

Attachments
Bulletin from the extraordinary general meeting and first control meeting in Asarina Pharma

Datum 2024-08-21, kl 11:30
Källa MFN
Bifogade filer
Bulletin from the extraordinary general meeting and first control meeting in Asarina Pharma
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!